Trial Profile
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms Measure Up 2
- Sponsors AbbVie; AbbVie Germany
- 06 Mar 2024 According to AbbVie media release, data from the study will be presented at American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.
- 11 Oct 2023 According to AbbVie media release, data from this study will be orally presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress
- 11 Oct 2023 Results published in the AbbVie Media Release